Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis
Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommen...
Gespeichert in:
| Veröffentlicht in: | The Pediatric infectious disease journal 2008-07, Vol.27 (7), p.660-661 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 661 |
|---|---|
| container_issue | 7 |
| container_start_page | 660 |
| container_title | The Pediatric infectious disease journal |
| container_volume | 27 |
| creator | Rodríguez, Susana P Fariña, Diana Bauer, Gabriela |
| description | Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT)4.5]. |
| doi_str_mv | 10.1097/INF.0b013e3181691753 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69306999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69306999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3290-957a2cb70039f87e654f98cc44f450cc98842cdc0d16869bb7e985b1b1471abb3</originalsourceid><addsrcrecordid>eNpdkUtv1DAQgC0EokvhHyDkC9xSxrHj2NxWq5ZWqqAqj6vleJ2uqddJPQkl_x5XXVGJw2gO881D3xDylsEJA91-vPhydgIdMO45U0xq1jb8GVmxhtcVaNU-JytQmlVcSnVEXiH-AgAuGLwkR0w1NQjRrsj-2uMYsp2GvNBvS3LLFGykP0OekV7lYdwt0f4JSEOilp6Hm111HfCWXg3jHO0UhvRQWecbn6aQ7Ce6ppsBp-q0772bwm-fPCJdJxsXDPiavOhtRP_mkI_Jj7PT75vz6vLr54vN-rJyvNZQ6aa1tevacq_uVetlI3qtnBOiFw04p5UStds62DKppO661mvVdKxjomW26_gx-fA4d8zD3exxMvuAzsdokx9mNFJzkFrrAopH0OUBMfvejDnsbV4MA_Og2RTN5n_Npe3dYf7c7f32qengtQDvD4BFZ2OfbXIB_3EFUpxp-bT_foiTz3gb53ufzc7bOO1MeRhI0YiqBlBQdEBVogb-F2QWli0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69306999</pqid></control><display><type>article</type><title>Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Rodríguez, Susana P ; Fariña, Diana ; Bauer, Gabriela</creator><creatorcontrib>Rodríguez, Susana P ; Fariña, Diana ; Bauer, Gabriela</creatorcontrib><description>Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT)4.5].</description><identifier>ISSN: 0891-3668</identifier><identifier>EISSN: 1532-0987</identifier><identifier>DOI: 10.1097/INF.0b013e3181691753</identifier><identifier>PMID: 18520447</identifier><identifier>CODEN: PIDJEV</identifier><language>eng</language><publisher>Baltimore, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal, Humanized ; Antiviral Agents - administration & dosage ; Antiviral Agents - pharmacology ; Argentina ; Biological and medical sciences ; Chemoprevention - economics ; Chemoprevention - methods ; Cost-Benefit Analysis ; General aspects ; Hospitalization - economics ; Human viral diseases ; Humans ; Immunomodulators ; Infant ; Infectious diseases ; Medical sciences ; Palivizumab ; Pharmacology. Drug treatments ; Respiratory Syncytial Virus Infections - economics ; Respiratory Syncytial Virus Infections - prevention & control ; Viral diseases ; Viral diseases of the respiratory system and ent viral diseases</subject><ispartof>The Pediatric infectious disease journal, 2008-07, Vol.27 (7), p.660-661</ispartof><rights>2008 Lippincott Williams & Wilkins, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3290-957a2cb70039f87e654f98cc44f450cc98842cdc0d16869bb7e985b1b1471abb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20483196$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18520447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodríguez, Susana P</creatorcontrib><creatorcontrib>Fariña, Diana</creatorcontrib><creatorcontrib>Bauer, Gabriela</creatorcontrib><title>Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis</title><title>The Pediatric infectious disease journal</title><addtitle>Pediatr Infect Dis J</addtitle><description>Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT)4.5].</description><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - pharmacology</subject><subject>Argentina</subject><subject>Biological and medical sciences</subject><subject>Chemoprevention - economics</subject><subject>Chemoprevention - methods</subject><subject>Cost-Benefit Analysis</subject><subject>General aspects</subject><subject>Hospitalization - economics</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Palivizumab</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory Syncytial Virus Infections - economics</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Viral diseases</subject><subject>Viral diseases of the respiratory system and ent viral diseases</subject><issn>0891-3668</issn><issn>1532-0987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1DAQgC0EokvhHyDkC9xSxrHj2NxWq5ZWqqAqj6vleJ2uqddJPQkl_x5XXVGJw2gO881D3xDylsEJA91-vPhydgIdMO45U0xq1jb8GVmxhtcVaNU-JytQmlVcSnVEXiH-AgAuGLwkR0w1NQjRrsj-2uMYsp2GvNBvS3LLFGykP0OekV7lYdwt0f4JSEOilp6Hm111HfCWXg3jHO0UhvRQWecbn6aQ7Ce6ppsBp-q0772bwm-fPCJdJxsXDPiavOhtRP_mkI_Jj7PT75vz6vLr54vN-rJyvNZQ6aa1tevacq_uVetlI3qtnBOiFw04p5UStds62DKppO661mvVdKxjomW26_gx-fA4d8zD3exxMvuAzsdokx9mNFJzkFrrAopH0OUBMfvejDnsbV4MA_Og2RTN5n_Npe3dYf7c7f32qengtQDvD4BFZ2OfbXIB_3EFUpxp-bT_foiTz3gb53ufzc7bOO1MeRhI0YiqBlBQdEBVogb-F2QWli0</recordid><startdate>200807</startdate><enddate>200807</enddate><creator>Rodríguez, Susana P</creator><creator>Fariña, Diana</creator><creator>Bauer, Gabriela</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200807</creationdate><title>Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis</title><author>Rodríguez, Susana P ; Fariña, Diana ; Bauer, Gabriela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3290-957a2cb70039f87e654f98cc44f450cc98842cdc0d16869bb7e985b1b1471abb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - pharmacology</topic><topic>Argentina</topic><topic>Biological and medical sciences</topic><topic>Chemoprevention - economics</topic><topic>Chemoprevention - methods</topic><topic>Cost-Benefit Analysis</topic><topic>General aspects</topic><topic>Hospitalization - economics</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Palivizumab</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory Syncytial Virus Infections - economics</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Viral diseases</topic><topic>Viral diseases of the respiratory system and ent viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodríguez, Susana P</creatorcontrib><creatorcontrib>Fariña, Diana</creatorcontrib><creatorcontrib>Bauer, Gabriela</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Pediatric infectious disease journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodríguez, Susana P</au><au>Fariña, Diana</au><au>Bauer, Gabriela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis</atitle><jtitle>The Pediatric infectious disease journal</jtitle><addtitle>Pediatr Infect Dis J</addtitle><date>2008-07</date><risdate>2008</risdate><volume>27</volume><issue>7</issue><spage>660</spage><epage>661</epage><pages>660-661</pages><issn>0891-3668</issn><eissn>1532-0987</eissn><coden>PIDJEV</coden><abstract>Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT)4.5].</abstract><cop>Baltimore, MD</cop><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>18520447</pmid><doi>10.1097/INF.0b013e3181691753</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-3668 |
| ispartof | The Pediatric infectious disease journal, 2008-07, Vol.27 (7), p.660-661 |
| issn | 0891-3668 1532-0987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69306999 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Argentina Biological and medical sciences Chemoprevention - economics Chemoprevention - methods Cost-Benefit Analysis General aspects Hospitalization - economics Human viral diseases Humans Immunomodulators Infant Infectious diseases Medical sciences Palivizumab Pharmacology. Drug treatments Respiratory Syncytial Virus Infections - economics Respiratory Syncytial Virus Infections - prevention & control Viral diseases Viral diseases of the respiratory system and ent viral diseases |
| title | Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A47%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Respiratory%20Syncytial%20Virus%20Prophylaxis%20in%20a%20High-Risk%20Population%20in%20Argentina:%20A%20Cost-Effectiveness%20Analysis&rft.jtitle=The%20Pediatric%20infectious%20disease%20journal&rft.au=Rodr%C3%ADguez,%20Susana%20P&rft.date=2008-07&rft.volume=27&rft.issue=7&rft.spage=660&rft.epage=661&rft.pages=660-661&rft.issn=0891-3668&rft.eissn=1532-0987&rft.coden=PIDJEV&rft_id=info:doi/10.1097/INF.0b013e3181691753&rft_dat=%3Cproquest_cross%3E69306999%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69306999&rft_id=info:pmid/18520447&rfr_iscdi=true |